China’s Abogen advancing mRNA vaccine for COVID-19, pipeline with $700M series C

The $700 million series C funding for mRNA vaccine developer Abogen is the biggest equity round in history for a biopharma based in China, and one of the largest private rounds ever for any biopharma, according to BioCentury’s BCIQ database.

Suzhou Abogen Biosciences Co. Ltd., which is led by founder and CEO Bo Ying, named seven leaders of the massive series C round, which will fund ongoing development of its mRNA-based vaccine for COVID-19. The group includes Temasek, Invesco Developing Markets Fund, Loyal Valley Capital, Hillhouse Capital’s GL Ventures, Yunfeng Capital, Lilly Asia Ventures and Boyu Capital...